Deutsche Bank AG Makes New Investment in Harmony Biosciences Holdings, Inc. $HRMY

Key Points

• Deutsche Bank acquired 101,612 shares of Harmony Biosciences during the second quarter, valued at approximately $3.7 million and representing a 0.17% stake. Institutional investors collectively own 86.23% of the company.
• Analyst sentiment remains mixed: four analysts rate HRMY a Buy, five Hold, and one Sell, resulting in a consensus Hold rating and an average price target of $45.50.
• Harmony reported quarterly earnings of $1.28 per share, beating estimates of $0.96, while revenue rose 30.3% year over year to $261.28 million. Shares opened at $38.95, near their 52-week high of $40.87.

Deutsche Bank AG acquired a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 101,612 shares of the company's stock, valued at approximately $3,700,000. Deutsche Bank AG owned 0.17% of Harmony Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in HRMY. EverSource Wealth Advisors LLC boosted its position in shares of Harmony Biosciences by 589.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company's stock valued at $28,000 after acquiring an additional 643 shares during the period. Allworth Financial LP raised its stake in Harmony Biosciences by 286.7% during the 4th quarter. Allworth Financial LP now owns 812 shares of the company's stock valued at $30,000 after purchasing an additional 602 shares during the last quarter. Leonteq Securities AG bought a new stake in Harmony Biosciences in the 4th quarter valued at $30,000. National Bank of Canada FI bought a new stake in Harmony Biosciences in the 3rd quarter valued at $40,000. Finally, Clearstead Advisors LLC grew its position in Harmony Biosciences by 145.9% in the 4th quarter. Clearstead Advisors LLC now owns 1,178 shares of the company's stock worth $44,000 after purchasing an additional 699 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on HRMY shares. UBS Group reiterated a "neutral" rating and issued a $37.00 target price on shares of Harmony Biosciences in a research note on Wednesday, August 5th. Truist Financial boosted their price objective on Harmony Biosciences from $29.00 to $34.00 and gave the company a "hold" rating in a research report on Wednesday, August 5th. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 target price on shares of Harmony Biosciences in a research report on Thursday, July 16th. Mizuho increased their price objective on shares of Harmony Biosciences from $50.00 to $51.00 and gave the company an "outperform" rating in a research note on Friday, July 31st. Finally, Wall Street Zen upgraded shares of Harmony Biosciences from a "buy" rating to a "strong-buy" rating in a research report on Sunday, August 16th. Four analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $45.50.

Harmony Biosciences Trading Up 1.2%

Shares of HRMY opened at $38.95 on Wednesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.45 and a current ratio of 3.48. The company has a market cap of $2.27 billion, a price-to-earnings ratio of 12.65, a PEG ratio of 0.36 and a beta of 0.96. The stock has a fifty day moving average price of $36.51 and a two-hundred day moving average price of $32.74. Harmony Biosciences Holdings, Inc. has a 52-week low of $25.52 and a 52-week high of $40.87.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $1.28 earnings per share for the quarter, beating analysts' consensus estimates of $0.96 by $0.32. Harmony Biosciences had a return on equity of 20.06% and a net margin of 18.88%.The company had revenue of $261.28 million during the quarter, compared to analyst estimates of $250.77 million. During the same period last year, the company posted $0.92 earnings per share. The firm's quarterly revenue was up 30.3% compared to the same quarter last year. Analysts predict that Harmony Biosciences Holdings, Inc. will post 3.77 EPS for the current fiscal year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company's mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company's flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.

Want to see what other hedge funds are holding HRMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.